(0.06%) 5 311.50 points
(0.07%) 40 173 points
(0.10%) 18 523 points
(1.68%) $82.72
(0.12%) $1.720
(0.85%) $2 231.50
(-0.08%) $24.73
(0.49%) $914.20
(0.33%) $0.926
(0.57%) $10.83
(0.10%) $0.792
(-0.08%) $92.37
@ $36.22
Issued: 14 Feb 2024 @ 15:47
Return: 22.67%
Previous signal: Feb 14 - 12:28
Previous signal:
Return: -0.41 %
Live Chart Being Loaded With Signals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors...
Stats | |
---|---|
Today's Volume | 823 483 |
Average Volume | 744 927 |
Market Cap | 3.46B |
EPS | $0 ( 2024-02-28 ) |
Next earnings date | ( $-0.840 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.04 |
ATR14 | $0.0380 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Knight Jeff E. | Sell | 30 000 | Stock Option (right to buy) |
2024-03-22 | Knight Jeff E. | Buy | 30 000 | Common Stock |
2024-03-22 | Knight Jeff E. | Sell | 30 000 | Common Stock |
2024-03-22 | Knight Jeff E. | Sell | 2 359 | Common Stock |
2024-03-20 | Pizzuti Dana | Sell | 4 375 | Stock Option (right to buy) |
INSIDER POWER |
---|
25.92 |
Last 99 transactions |
Buy: 1 520 833 | Sell: 975 029 |
Volume Correlation
Crinetics Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
VYNE | 0.883 |
CPIX | 0.875 |
FULC | 0.871 |
ARWR | 0.869 |
RDUS | 0.866 |
LITM | 0.861 |
RNDM | 0.858 |
SPRO | 0.857 |
JAKK | 0.844 |
ENTA | 0.841 |
10 Most Negative Correlations | |
---|---|
ALGM | -0.894 |
SITM | -0.856 |
GMII | -0.853 |
PPBT | -0.85 |
GDRX | -0.835 |
UMPQ | -0.821 |
GFS | -0.815 |
SBBP | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Crinetics Pharmaceuticals Correlation - Currency/Commodity
Crinetics Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $4.01M |
Gross Profit: | $2.92M (72.64 %) |
EPS: | $-3.69 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-262 000 (0.00 %) |
EPS: | $-0.900 |
Q3 | 2023 |
Revenue: | $346 000 |
Gross Profit: | $73 000.00 (21.10 %) |
EPS: | $-1.010 |
Q2 | 2023 |
Revenue: | $988 000 |
Gross Profit: | $590 000 (59.72 %) |
EPS: | $-0.940 |
Financial Reports:
No articles found.
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators